Naïve T cells can commit to effector [T helper 1 (Th1), Th2 and Th17] or regulatory lineages. Skewing of responses toward inflammatory Th1, Th2 or Th17 pathways and away from regulatory T-cell pathways might be responsible for the initiation and progress of immune-mediated diseases. Based on recent data, we propose that interleukin-21 (IL-21), a cytokine produced by activated CD4+ T cells, induces the development of Th17 cells, blocks the differentiation of transforming growth factor-β1-induced regulatory T cells and renders CD4+ T cells resistant to the suppressive effects of regulatory T cells, thereby playing a major role in pathogenic T-cell responses. © 2008 Elsevier Ltd. All rights reserved.
Monteleone, G., Pallone, F., Macdonald, T.t. (2008). Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. TRENDS IN IMMUNOLOGY, 29(6), 290-294 [10.1016/j.it.2008.02.008].
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses
MONTELEONE, GIOVANNI;PALLONE, FRANCESCO;
2008-01-01
Abstract
Naïve T cells can commit to effector [T helper 1 (Th1), Th2 and Th17] or regulatory lineages. Skewing of responses toward inflammatory Th1, Th2 or Th17 pathways and away from regulatory T-cell pathways might be responsible for the initiation and progress of immune-mediated diseases. Based on recent data, we propose that interleukin-21 (IL-21), a cytokine produced by activated CD4+ T cells, induces the development of Th17 cells, blocks the differentiation of transforming growth factor-β1-induced regulatory T cells and renders CD4+ T cells resistant to the suppressive effects of regulatory T cells, thereby playing a major role in pathogenic T-cell responses. © 2008 Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.